<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
         xmlns="http://purl.org/rss/1.0/"
         xmlns:admin="http://webns.net/mvcb/"
         xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
         xmlns:dc="http://purl.org/dc/elements/1.1/"
         xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
  <channel rdf:about="https://hstalks.com/rss/by-category/763/">
    <title>Clinical Practice</title>
    <link>https://hstalks.com/category/763/clinical-practice/?biosci</link>
    <description>New and updated series &amp; talks on Clinical Practice from HSTalks&#x27; Biomedical &amp; Life Sciences Collection.</description>
    <admin:generatorAgent rdf:resource="http://www.hstalks.com/" />
    <admin:errorReportsTo rdf:resource="mailto:info@hstalks.com" />
    <sy:updatePeriod>daily</sy:updatePeriod>
    <sy:updateFrequency>1</sy:updateFrequency>
    <sy:updateBase>2006-01-01T12:00+00:00</sy:updateBase>
    <dc:publisher>Henry Stewart Talks</dc:publisher>
    <dc:language>en</dc:language>
    <dc:rights>© Copyright Henry Stewart Talks Ltd.</dc:rights>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
    <prism:copyright>© Copyright Henry Stewart Talks Ltd.</prism:copyright>
    <items>
      <rdf:Seq>
      <rdf:li resource="https://hstalks.com/t/3391/palin-parent-child-interaction-therapy/?biosci" />
      <rdf:li resource="https://hstalks.com/t/3602/bridging-our-mandates-evidence-based-practice-ebp-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/3603/bridging-our-mandates-evidence-based-practice-ebp-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/3404/teenagers-and-stuttering-management-are-they-ready/?biosci" />
      <rdf:li resource="https://hstalks.com/t/3588/treatment-of-stuttering-during-the-pre-school-year/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27464/clinical-research-ethics/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23026/gene-therapies-economics-access-barriers-commercia/?biosci" />
      <rdf:li resource="https://hstalks.com/t/24084/the-environment-scleroderma/?biosci" />
      <rdf:li resource="https://hstalks.com/t/27463/good-clinical-practice/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22796/parasitic-diseases-causes-mechanisms-and-clinical-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22102/walking-on-water-load-bearing-joint-perfusion-and-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23059/risdiplam-for-prenatal-therapy-of-spinal-muscular-/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22432/growth-screening-and-rare-disease/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22071/routine-growth-screening-does-it-measure-up-1/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22366/routine-growth-screening-does-it-measure-up-2/?biosci" />
      <rdf:li resource="https://hstalks.com/t/12730/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci" />
      <rdf:li resource="https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci" />
      <rdf:li resource="https://hstalks.com/t/22202/us-privacy-law-and-digital-therapeutics/?biosci" />
      <rdf:li resource="https://hstalks.com/t/21277/technology-for-individuals-with-autism-spectrum-di/?biosci" />
      <rdf:li resource="https://hstalks.com/t/25006/introduction-to-the-female-pelvis-and-perineum/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23356/duchenne-muscular-dystrophy-advances-in-research-t/?biosci" />
      <rdf:li resource="https://hstalks.com/t/25898/haemodynamic-disorders/?biosci" />
      <rdf:li resource="https://hstalks.com/t/25902/osteoarthritis/?biosci" />
      <rdf:li resource="https://hstalks.com/t/24808/an-overview-of-the-vascular-and-lymphatic-systems/?biosci" />
      <rdf:li resource="https://hstalks.com/t/25905/preclinical-to-clinical-translation/?biosci" />
      
      </rdf:Seq>
    </items>
  </channel>

  <item rdf:about="https://hstalks.com/t/3391/palin-parent-child-interaction-therapy/?biosci">
    <title>Palin parent-child interaction therapy [33 mins] </title>
    <link>https://hstalks.com/t/3391/palin-parent-child-interaction-therapy/?biosci</link>
    <description>Multifactorial model of onset &amp; development of stuttering - Therapeutic approach: core values - Risk factors for young children who stutter - Screening for vulnerability to persistence and appropriate care pathways - Assessment of stuttering - Principles of Palin parent-child interaction (PCI) therapy - Using video analysis in PCI therapy - Three main strands of PCI therapy: interaction, family, child (strategies)</description>
    <dc:title>Palin parent-child interaction therapy</dc:title>
    
    <dc:creator>Ms. Elaine Kelman</dc:creator>
    
    <dc:subject>Multifactorial model of onset &amp; development of stuttering, Therapeutic approach: core values, Risk factors for young children who stutter, Screening for vulnerability to persistence and appropriate care pathways, Assessment of stuttering, Principles of Palin parent-child interaction (PCI) therapy, Using video analysis in PCI therapy, Three main strands of PCI therapy: interaction, family, child (strategies)</dc:subject>
    <dc:date>2026-11-03</dc:date>
    <prism:publicationDate>2026-11-03</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/3602/bridging-our-mandates-evidence-based-practice-ebp-/?biosci">
    <title>Bridging our mandates: evidence-based practice (EBP) and patient-centered care (PCC) 1 [33 mins] </title>
    <link>https://hstalks.com/t/3602/bridging-our-mandates-evidence-based-practice-ebp-/?biosci</link>
    <description>Principles of evidence-based practice (EBP) - The process model - Linear vs. continuous EBP - Changing therapy approaches - Treatment of early stuttering - The acceptable time to wait for therapy progress - Patient-centered care (PCC) - Seeking a single best therapy for any condition - Important questions that need asking</description>
    <dc:title>Bridging our mandates: evidence-based practice (EBP) and patient-centered care (PCC) 1</dc:title>
    
    <dc:creator>Prof. Nan Bernstein Ratner</dc:creator>
    
    <dc:subject>Principles of evidence-based practice (EBP), The process model, Linear vs. continuous EBP, Changing therapy approaches, Treatment of early stuttering, The acceptable time to wait for therapy progress, Patient-centered care (PCC), Seeking a single best therapy for any condition, Important questions that need asking</dc:subject>
    <dc:date>2026-11-02</dc:date>
    <prism:publicationDate>2026-11-02</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/3603/bridging-our-mandates-evidence-based-practice-ebp-/?biosci">
    <title>Bridging our mandates: evidence-based practice (EBP) and patient-centered care (PCC) 2 [31 mins] </title>
    <link>https://hstalks.com/t/3603/bridging-our-mandates-evidence-based-practice-ebp-/?biosci</link>
    <description>Practice-based evidence (PBE) - &#x27;Evidence-farming&#x27; (harnessing PBE) - Benefits of evidence farming - Outcome due to &quot;good&quot; therapy approaches - Common factors in therapy - Clinician matters as much as the therapy - Factors that tend to enhance patient-centered care - The precarious place of clinical educators</description>
    <dc:title>Bridging our mandates: evidence-based practice (EBP) and patient-centered care (PCC) 2</dc:title>
    
    <dc:creator>Prof. Nan Bernstein Ratner</dc:creator>
    
    <dc:subject>Practice-based evidence (PBE), &#x27;Evidence-farming&#x27; (harnessing PBE), Benefits of evidence farming, Outcome due to &quot;good&quot; therapy approaches, Common factors in therapy, Clinician matters as much as the therapy, Factors that tend to enhance patient-centered care, The precarious place of clinical educators</dc:subject>
    <dc:date>2026-11-02</dc:date>
    <prism:publicationDate>2026-11-02</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/3404/teenagers-and-stuttering-management-are-they-ready/?biosci">
    <title>Teenagers and stuttering management: are they ready? [55 mins] </title>
    <link>https://hstalks.com/t/3404/teenagers-and-stuttering-management-are-they-ready/?biosci</link>
    <description>Motivation - Readiness can change - Motivational interviewing - The stages of change model - Decisional balance - Self-efficacy - Staging algorithm: stuttering management - UISPEAKS program for teens - Therapy map</description>
    <dc:title>Teenagers and stuttering management: are they ready?</dc:title>
    
    <dc:creator>Prof. Patricia Zebrowski</dc:creator>
    
    <dc:subject>Motivation, Readiness can change, Motivational interviewing, The stages of change model, Decisional balance, Self-efficacy, Staging algorithm: stuttering management, UISPEAKS program for teens, Therapy map</dc:subject>
    <dc:date>2026-11-02</dc:date>
    <prism:publicationDate>2026-11-02</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/3588/treatment-of-stuttering-during-the-pre-school-year/?biosci">
    <title>Treatment of stuttering during the pre-school years [19 mins] </title>
    <link>https://hstalks.com/t/3588/treatment-of-stuttering-during-the-pre-school-year/?biosci</link>
    <description>Treatment of stuttering during the preschool years - Why treat early stuttering? - Two different types of treatment - Clinical trials - Advantages and disadvantages of two types of treatment - The future for the field</description>
    <dc:title>Treatment of stuttering during the pre-school years</dc:title>
    
    <dc:creator>Prof. Mark Onslow</dc:creator>
    
    <dc:subject>Treatment of stuttering during the preschool years, Why treat early stuttering?, Two different types of treatment, Clinical trials, Advantages and disadvantages of two types of treatment, The future for the field</dc:subject>
    <dc:date>2026-11-01</dc:date>
    <prism:publicationDate>2026-11-01</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27464/clinical-research-ethics/?biosci">
    <title>Clinical research ethics [4 mins] </title>
    <link>https://hstalks.com/t/27464/clinical-research-ethics/?biosci</link>
    <description>Clinical research ethics history - Key ethical frameworks - Informed consent processes - Participant rights and safety - Ethics committee oversight - Risk-benefit analysis in research</description>
    <dc:title>Clinical research ethics</dc:title>
    
    
    <dc:subject>Clinical research ethics history, Key ethical frameworks, Informed consent processes, Participant rights and safety, Ethics committee oversight, Risk-benefit analysis in research</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci">
    <title>Targeting the intestinal barrier in GVHD and checkpoint colitis [20 mins] </title>
    <link>https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci</link>
    <description>Acute graft-versus-host disease (aGVHD): Clinical presentation - Intestinal inflammation during aGVHD - Treatment of aGVHD - Kinase targets in GVHD - REACH2 trial - Colitis and other irAEs after immune checkpoint blockade - ECP is an effective therapy for inflammatory diseases - Arginase-1 is central in ECP-induced immunomodulation</description>
    <dc:title>Targeting the intestinal barrier in GVHD and checkpoint colitis</dc:title>
    
    <dc:creator>Prof. Robert Zeiser</dc:creator>
    
    <dc:subject>Acute graft-versus-host disease (aGVHD): Clinical presentation, Intestinal inflammation during aGVHD, Treatment of aGVHD, Kinase targets in GVHD, REACH2 trial, Colitis and other irAEs after immune checkpoint blockade, ECP is an effective therapy for inflammatory diseases, Arginase-1 is central in ECP-induced immunomodulation</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23026/gene-therapies-economics-access-barriers-commercia/?biosci">
    <title>Gene therapies: economics, access barriers &amp; commercial models [41 mins] </title>
    <link>https://hstalks.com/t/23026/gene-therapies-economics-access-barriers-commercia/?biosci</link>
    <description>Gene therapy - Rare diseases - Economic challenges of gene therapies - Patient access - Real world evidences - Health technology assessment - Patient advocacy groups - Clinical development plan - Market development plant</description>
    <dc:title>Gene therapies: economics, access barriers &amp; commercial models</dc:title>
    
    <dc:creator>Dr. Kasem S. Akhras</dc:creator>
    
    <dc:subject>Gene therapy, Rare diseases, Economic challenges of gene therapies, Patient access, Real world evidences, Health technology assessment, Patient advocacy groups, Clinical development plan, Market development plant</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/24084/the-environment-scleroderma/?biosci">
    <title>The environment &amp; scleroderma [12 mins] </title>
    <link>https://hstalks.com/t/24084/the-environment-scleroderma/?biosci</link>
    <description>Systemic sclerosis (scleroderma) - Pathogenesis of systemic sclerosis (SSc) - Gene-susceptibility and gene-environment interaction in SSc - Environmental risk factors - Epigenetic impact of toxins - Infectious triggers - Microbiome alteration in SSc - Medications associated with scleroderma-like skin changes or scleroderma</description>
    <dc:title>The environment &amp; scleroderma</dc:title>
    
    <dc:creator>Dr. Zsuzsanna McMahan</dc:creator>
    
    <dc:subject>Systemic sclerosis (scleroderma), Pathogenesis of systemic sclerosis (SSc), Gene-susceptibility and gene-environment interaction in SSc, Environmental risk factors, Epigenetic impact of toxins, Infectious triggers, Microbiome alteration in SSc, Medications associated with scleroderma-like skin changes or scleroderma</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/27463/good-clinical-practice/?biosci">
    <title>Good clinical practice [4 mins] </title>
    <link>https://hstalks.com/t/27463/good-clinical-practice/?biosci</link>
    <description>Good Clinical Practice Essentials - GCP Ethical Foundations - Informed Consent Importance - Scientific and Methodological Needs - Regulatory Compliance and Harmonization - Quality Assurance and Monitoring</description>
    <dc:title>Good clinical practice</dc:title>
    
    
    <dc:subject>Good Clinical Practice Essentials, GCP Ethical Foundations, Informed Consent Importance, Scientific and Methodological Needs, Regulatory Compliance and Harmonization, Quality Assurance and Monitoring</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22796/parasitic-diseases-causes-mechanisms-and-clinical-/?biosci">
    <title>Parasitic diseases: causes, mechanisms, and clinical examples [26 mins] </title>
    <link>https://hstalks.com/t/22796/parasitic-diseases-causes-mechanisms-and-clinical-/?biosci</link>
    <description>Parasitic diseases - Types of parasites - Parasite’s inherent characteristics - Parasitic mechanisms of cell and tissue damage - Clinical examples of parasitic diseases - Diagnostic methods - Treatment - Prevention</description>
    <dc:title>Parasitic diseases: causes, mechanisms, and clinical examples</dc:title>
    
    <dc:creator>Prof. Hany Elsheikha</dc:creator>
    
    <dc:subject>Parasitic diseases, Types of parasites, Parasite’s inherent characteristics, Parasitic mechanisms of cell and tissue damage, Clinical examples of parasitic diseases, Diagnostic methods, Treatment, Prevention</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22102/walking-on-water-load-bearing-joint-perfusion-and-/?biosci">
    <title>Walking on water: load bearing, joint perfusion and osteoarthritis [24 mins] </title>
    <link>https://hstalks.com/t/22102/walking-on-water-load-bearing-joint-perfusion-and-/?biosci</link>
    <description>Joints - IOP measurement - Factor affecting IOP measurements - Significance of IOPv - IOPa - Load - Vascular markings in MRI scans - Correlation between vascular marks and Kellgren - Lawrence grade - Bone histology - Choke valve</description>
    <dc:title>Walking on water: load bearing, joint perfusion and osteoarthritis</dc:title>
    
    <dc:creator>Dr. Michael Beverly</dc:creator>
    
    <dc:subject>Joints, IOP measurement, Factor affecting IOP measurements, Significance of IOPv, IOPa, Load, Vascular markings in MRI scans, Correlation between vascular marks and Kellgren, Lawrence grade, Bone histology, Choke valve</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23059/risdiplam-for-prenatal-therapy-of-spinal-muscular-/?biosci">
    <title>Risdiplam for prenatal therapy of spinal muscular atrophy [14 mins] </title>
    <link>https://hstalks.com/t/23059/risdiplam-for-prenatal-therapy-of-spinal-muscular-/?biosci</link>
    <description>Spinal muscular atrophy (SMA) - Prenatal therapy - Fetal medicine - Risdiplam - SMN2 splicing modulation - Genetic disorders - Pediatric neurology - Translational medicine - Rare diseases - In utero treatment</description>
    <dc:title>Risdiplam for prenatal therapy of spinal muscular atrophy</dc:title>
    
    <dc:creator>Dr. Richard Finkel</dc:creator>
    
    <dc:subject>Spinal muscular atrophy (SMA), Prenatal therapy, Fetal medicine, Risdiplam, SMN2 splicing modulation, Genetic disorders, Pediatric neurology, Translational medicine, Rare diseases, In utero treatment</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22432/growth-screening-and-rare-disease/?biosci">
    <title>Growth screening and rare disease [27 mins] </title>
    <link>https://hstalks.com/t/22432/growth-screening-and-rare-disease/?biosci</link>
    <description>Importance and limitations of routine growth testing - Rare disease specific growth curves - Prader Willi Syndrome (PWS) - Future of routine growth screening - Pediatric genetic testing</description>
    <dc:title>Growth screening and rare disease</dc:title>
    
    <dc:creator>Prof. Natasha Shur</dc:creator>
    
    <dc:subject>Importance and limitations of routine growth testing, Rare disease specific growth curves, Prader Willi Syndrome (PWS), Future of routine growth screening, Pediatric genetic testing</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22071/routine-growth-screening-does-it-measure-up-1/?biosci">
    <title>Routine growth screening: does it measure up? 1 [29 mins] </title>
    <link>https://hstalks.com/t/22071/routine-growth-screening-does-it-measure-up-1/?biosci</link>
    <description>Pediatric care - Brief history of screening growth - Routine growth screening - CDC versus WHO - Growth curves</description>
    <dc:title>Routine growth screening: does it measure up? 1</dc:title>
    
    <dc:creator>Prof. Natasha Shur</dc:creator>
    
    <dc:subject>Pediatric care, Brief history of screening growth, Routine growth screening, CDC versus WHO, Growth curves</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22366/routine-growth-screening-does-it-measure-up-2/?biosci">
    <title>Routine growth screening: does it measure up? 2 [9 mins] </title>
    <link>https://hstalks.com/t/22366/routine-growth-screening-does-it-measure-up-2/?biosci</link>
    <description>Case studies - Numbers behind the growth curve - Hydrocephalus - Growth curves - Limitations to growth screening</description>
    <dc:title>Routine growth screening: does it measure up? 2</dc:title>
    
    <dc:creator>Prof. Natasha Shur</dc:creator>
    
    <dc:subject>Case studies, Numbers behind the growth curve, Hydrocephalus, Growth curves, Limitations to growth screening</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/12730/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci">
    <title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: introduction to bladder cancer [36 mins] </title>
    <link>https://hstalks.com/t/12730/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci</link>
    <description>Bladder cancer: incidence and epidemiology - Bladder cancer risk factors - Lynch syndrome - Bladder cancer: pathology, staging and diagnosis - Initial therapy for NMIBC (non-muscle-invasive bladder cancer)</description>
    <dc:title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: introduction to bladder cancer</dc:title>
    
    <dc:creator>Prof. Guru P. Sonpavde</dc:creator>
    
    <dc:subject>Bladder cancer: incidence and epidemiology, Bladder cancer risk factors, Lynch syndrome, Bladder cancer: pathology, staging and diagnosis, Initial therapy for NMIBC (non-muscle-invasive bladder cancer)</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci">
    <title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials [37 mins] </title>
    <link>https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci</link>
    <description>Ongoing clinical trials for bladder cancer - Enfortumab-vedotin &amp; pembrolizumab as first-line therapy - Disitamab vedotin &amp; toripalimab (PD1 inhibitor) for the treatment of metastatic UC - Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions - Remission with cisplatin-based NAC - mRNA-4157 (V940): customizable individualized mRNA immunotherapy - Adjuvant chemotherapy - Neoadjuvant Chemo-IO combination therapy</description>
    <dc:title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials</dc:title>
    
    <dc:creator>Prof. Guru P. Sonpavde</dc:creator>
    
    <dc:subject>Ongoing clinical trials for bladder cancer, Enfortumab-vedotin &amp; pembrolizumab as first-line therapy, Disitamab vedotin &amp; toripalimab (PD1 inhibitor) for the treatment of metastatic UC, Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions, Remission with cisplatin-based NAC, mRNA-4157 (V940): customizable individualized mRNA immunotherapy, Adjuvant chemotherapy, Neoadjuvant Chemo-IO combination therapy</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/22202/us-privacy-law-and-digital-therapeutics/?biosci">
    <title>U.S. privacy law and digital therapeutics [48 mins] </title>
    <link>https://hstalks.com/t/22202/us-privacy-law-and-digital-therapeutics/?biosci</link>
    <description>Digital Therapeutics - Digital Health - Virtual Care - US FDA - HIPAA - Privacy - Security - US FTC</description>
    <dc:title>U.S. privacy law and digital therapeutics</dc:title>
    
    <dc:creator>Ms. Lucia C. Savage</dc:creator>
    
    <dc:subject>Digital Therapeutics, Digital Health, Virtual Care, US FDA, HIPAA, Privacy, Security, US FTC</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/21277/technology-for-individuals-with-autism-spectrum-di/?biosci">
    <title>Technology for individuals with autism spectrum disorders [23 mins] </title>
    <link>https://hstalks.com/t/21277/technology-for-individuals-with-autism-spectrum-di/?biosci</link>
    <description>Assistive technology - SETT - Visual supports - Executive function skills and behavior - Technology for reading, writing and note taking - Upcoming technologies</description>
    <dc:title>Technology for individuals with autism spectrum disorders</dc:title>
    
    <dc:creator>Dr. Bogdan Zamfir</dc:creator>
    
    <dc:subject>Assistive technology, SETT, Visual supports, Executive function skills and behavior, Technology for reading, writing and note taking, Upcoming technologies</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/25006/introduction-to-the-female-pelvis-and-perineum/?biosci">
    <title>Introduction to the female pelvis and perineum [45 mins] </title>
    <link>https://hstalks.com/t/25006/introduction-to-the-female-pelvis-and-perineum/?biosci</link>
    <description>Superficial topography of female pelvis - Bones, ligaments and muscles of female pelvis - Pelvic diaphragm and perineal body - Female pelvic organs - Arterial and venous blood supply - Lymphatic drainage - Examples of diseases affecting the female pelvis and perineum</description>
    <dc:title>Introduction to the female pelvis and perineum</dc:title>
    
    <dc:creator>Prof. Diogo Pais</dc:creator>
    
    <dc:subject>Superficial topography of female pelvis, Bones, ligaments and muscles of female pelvis, Pelvic diaphragm and perineal body, Female pelvic organs, Arterial and venous blood supply, Lymphatic drainage, Examples of diseases affecting the female pelvis and perineum</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23356/duchenne-muscular-dystrophy-advances-in-research-t/?biosci">
    <title>Duchenne muscular dystrophy: advances in research, treatment, and clinical management [13 mins] </title>
    <link>https://hstalks.com/t/23356/duchenne-muscular-dystrophy-advances-in-research-t/?biosci</link>
    <description>Duchenne muscular dystrophy causes and management - Dystrophin - Rare disease - Muscle wasting - Approved therapies for Duchenne</description>
    <dc:title>Duchenne muscular dystrophy: advances in research, treatment, and clinical management</dc:title>
    
    <dc:creator>Prof. Annemieke Aartsma-Rus</dc:creator>
    
    <dc:subject>Duchenne muscular dystrophy causes and management, Dystrophin, Rare disease, Muscle wasting, Approved therapies for Duchenne</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/25898/haemodynamic-disorders/?biosci">
    <title>Haemodynamic disorders [4 mins] </title>
    <link>https://hstalks.com/t/25898/haemodynamic-disorders/?biosci</link>
    <description>Normal haemodynamics - Haemodynamic disorders - Oedema and thrombosis - Types of shock - Diagnosis and management of haemodynamic disorders</description>
    <dc:title>Haemodynamic disorders</dc:title>
    
    
    <dc:subject>Normal haemodynamics, Haemodynamic disorders, Oedema and thrombosis, Types of shock, Diagnosis and management of haemodynamic disorders</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/25902/osteoarthritis/?biosci">
    <title>Osteoarthritis [4 mins] </title>
    <link>https://hstalks.com/t/25902/osteoarthritis/?biosci</link>
    <description>Osteoarthritis definition and pathology - Causes of osteoarthritis - Current treatment limitations - New therapeutic targets and research - Role of biomarkers in diagnosis and treatment</description>
    <dc:title>Osteoarthritis</dc:title>
    
    
    <dc:subject>Osteoarthritis definition and pathology, Causes of osteoarthritis, Current treatment limitations, New therapeutic targets and research, Role of biomarkers in diagnosis and treatment</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/24808/an-overview-of-the-vascular-and-lymphatic-systems/?biosci">
    <title>An overview of the vascular and lymphatic systems [24 mins] </title>
    <link>https://hstalks.com/t/24808/an-overview-of-the-vascular-and-lymphatic-systems/?biosci</link>
    <description>Circulatory system - Cardiovascular system - Structure and function of lymphatic system - Portal venous system - Clinical significance: Lymphedema - Lymph nodes - Clinical significance: Cancer spread</description>
    <dc:title>An overview of the vascular and lymphatic systems</dc:title>
    
    <dc:creator>Dr. Larissa Nelson</dc:creator>
    
    <dc:subject>Circulatory system, Cardiovascular system, Structure and function of lymphatic system, Portal venous system, Clinical significance: Lymphedema, Lymph nodes, Clinical significance: Cancer spread</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/25905/preclinical-to-clinical-translation/?biosci">
    <title>Preclinical to clinical translation [5 mins] </title>
    <link>https://hstalks.com/t/25905/preclinical-to-clinical-translation/?biosci</link>
    <description>Preclinical to clinical translation - Animal model challenges - Biomarker role and validation - PK/PD data integration - Early phase trial design pitfalls - Continual learning and scientific rigor - Collaboration in therapy development</description>
    <dc:title>Preclinical to clinical translation</dc:title>
    
    
    <dc:subject>Preclinical to clinical translation, Animal model challenges, Biomarker role and validation, PK/PD data integration, Early phase trial design pitfalls, Continual learning and scientific rigor, Collaboration in therapy development</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

</rdf:RDF>
